Aromatase inhibitors reduce estrogen levels by blocking aromatase activity in peripheral adipose and tumor tissue (13).GnRH-a suppress ovarian estrogen production by inhibiting the pituitary ovarian axis, leading to a “postmenopausal” status; moreover, GnRH-a may have an additive action by blocking the intra-tumoral GnRH receptor (11, 13). Here, CYP19A1 is linked to neoplasm.